Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: Novel multicomponent delivery system

Cancer Research

Volumn 64, Issue 17, 2004, Pages 6214-6224

  Pakunlu, Refika I ^a   Wang, Yang ^a   Tsao, William ^a   Pozharov, Vitaly ^a   Cook, Thomas J ^a   Minko, Tamara ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE; DOXORUBICIN; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BCL2 GENE; CANCER CELL; CANCER CHEMOTHERAPY; CELL NUCLEUS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESISTANCE; DRUG TRANSPORT; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG CANCER; LUNG SMALL CELL CANCER; MRP1 GENE; PRIORITY JOURNAL;

APOPTOSIS; CARCINOMA, SMALL CELL; CASPASE 3; CASPASES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 4344571205     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0001     Document Type: Article

References (28)

1. Pakunlu RI, Cook TJ, Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res 2003;20:351-9.
2. Minko T, Dharap SS, Pakunlu RI, Wang Y. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004;5:389-406.
3. Szakacs G, Jakab K, Antal F, Sarkadi B. Diagnostics of multidrug resistance in cancer. Pathol Oncol Res 1998;4:251-7.
4. van Veen HW, Konings WN. The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta 1998;1365:31-6.
5. Scagliotti GV, Novello S, Selvaggi G. Multidrug resistance in non-small-cell lung cancer. Ann Oncol 1999;10(Suppl 5):S83-6.
6. Nakamura M, Abe Y, Katoh Y, et al. A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration. Anticancer Res 2000;20:1921-5.
7. Hsia TC, Lin CC, Wang JJ, Ho ST, Kao A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 2002;180:173-9.
8. Alahary SK, DeLong R, Fisher MH, et al. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther 1998;286:419-28.
9. Corrias MV, Tonini GP. An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res 1992;12:1431-8.
10. Motomura S, Motoji T, Takanashi M, et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 1998;91:3163-71.
11. Rebowski G, Wojcik M, Boczkowska M, et al. Antisense hairpin loop oligonucleotides as inhibitors of expression of multidrug resistance-associated protein 1: their stability in fetal calf serum and human plasma. Acta Biochim Pol 2001;48:1061-76.
12. Stewart AJ, Canitrot Y, Baracchini E, et al. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 1996;51:461-9.
13. Yang JY, Luo HY, Lin V, et al. Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R. World J Gastroenterol 2002;8:644-9.
14. Gross A, McDonnell JM, Korsmeyer, S. BCL2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
15. Reed J. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
16. Konopleva M, Tan AM, Estrov Z, et al. Liposomal BCL2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000;15: 3929-38.
17. de Mendes DEL, Hudon N, McIntosh N, Mayer LD. Molecular and pharmacokinetics properties associated with the therapeutics of BCL2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000;6:2891-902.
18. Poulaki V, Mitsiades N, Romero ME, Tsokos M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and BCL2. Cancer Res 2001;61:4864-72.
19. Tari A, Tucker S, Deisseroth A, Lopez-Berestein GF. Liposomal delivery of methylphosphonate antisense oligonucleotides in chronic myelogenous leukemia. Blood 1994;84:601-7.
20. Wang Y, Pakunlu RI, Tsao W, Pozharov V, Minko T. Bimodal effect of hypoxia in cancer: the role of hypoxia inducible factor in apoptosis. Mol Pharmacol 2004;1: 156-65.
21. Tsukioka Y, Matsumura Y, Hamaguchi T, et al. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J Cancer Res 2002;93:1145-53.
22. Minko T, Kopeckova P, Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 2000;86:108-17.
23. Minko T, Dharap SS, Fabbricatore AT. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense. Cancer Detect Prev 2003:27:193-202.
24. Dharap SS, Minko T. Targeted proapoptotic LHRH-BH3 peptide. Pharm Res 2003; 20:889-96.
25. Dharap SS, Qiu B, Williams G, et al. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Controlled Release 2003;91:61-73.
26. Minko T, Kopeckova P, Pozharov V, Kopecek, J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Controlled Release 1998;54:223-33.
27. Minko T, Paranjpe P, Qiu B, et al. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 2002;50:143-50.
28. Minko T, Dharap SS, Pakunlu RI, Colaizzi JL. Advanced drug delivery systems in cancer chemotherapy. Dis Management Clin Outcomes 2001;3:48-54.